drugset / Trial / NCT05508620
A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, multi-center phase 1b study to evaluate the safety and efficacy of Sirolimus for injection (albumin-bound) in patients with malignant solid tumors with TSC1 or TSC2 genetic alterations.
Timeline
- Start
- 2022-10
- Primary completion
- 2024-12
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sirolimus | Small molecule | — | Intravenous |